Author

M. Arellano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Plant Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:plant (other)· 1

Frequent Co-Authors

A. Curti· 1 shared B. Lowenberg· 1 shared C. Hodar· 1 shared C. Lai· 1 shared C. Ponce· 1 shared E. Carrera· 1 shared F. Correa· 1 shared F. Ravandi· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Curti

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transcriptomic and DNA methylation modifications during fruit ripening and in response to ABA treatment in sweet cherry

N. Kuhn, M. Arellano, C. Ponce, C. Hodar, F. Correa, S. Multari, S. Martens, E. Carrera, J. M. Donoso, L. A. Meisel

This study examines transcriptomic and DNA methylation changes in sweet cherry during ripening and in response to ABA treatment, revealing gene expression and epigenetic modifications related to ripening processes.

bioRxiv · Dec 2, 2022 · PreprintPlant Biology

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

C. Lai, J. Vadakekolathu, S. Reeder, S. E. Church, T. Hood, I. Aldoss, J. Godwin, M. J. Wieduwilt, M. Arellano, J. Muth, F. Ravandi, K. Sweet, H. Altmann, G. A. Foulds, F. Stolzel, , S. Rutella

This paper shows TP53 mutations in AML are linked to immune features and improved response to flotetuzumab immunotherapy.

bioRxiv · Feb 28, 2020 · PreprintImmunology